- Home
- NDMO vs NRIX Comparison
NDMO vs NRIX Comparison
Compare NDMO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- NRIX
- Stock Information
- Founded
- NDMO 2019
- NRIX 2009
- Country
- NDMO United States
- NRIX United States
- Employees
- NDMO N/A
- NRIX N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- NDMO Finance
- NRIX Health Care
- Exchange
- NDMO Nasdaq
- NRIX Nasdaq
- Market Cap
- NDMO 620.6M
- NRIX 728.6M
- IPO Year
- NDMO N/A
- NRIX 2020
- Fundamental
- Price
- NDMO $10.34
- NRIX $8.57
- Analyst Decision
- NDMO
- NRIX Strong Buy
- Analyst Count
- NDMO 0
- NRIX 14
- Target Price
- NDMO N/A
- NRIX $29.07
- AVG Volume (30 Days)
- NDMO 218.6K
- NRIX 786.7K
- Earning Date
- NDMO 01-01-0001
- NRIX 10-10-2025
- Dividend Yield
- NDMO 6.75%
- NRIX N/A
- EPS Growth
- NDMO N/A
- NRIX N/A
- EPS
- NDMO N/A
- NRIX N/A
- Revenue
- NDMO N/A
- NRIX $88,381,000.00
- Revenue This Year
- NDMO N/A
- NRIX $74.59
- Revenue Next Year
- NDMO N/A
- NRIX N/A
- P/E Ratio
- NDMO N/A
- NRIX N/A
- Revenue Growth
- NDMO N/A
- NRIX 41.86
- 52 Week Low
- NDMO $8.99
- NRIX $8.18
- 52 Week High
- NDMO $11.24
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- NDMO 66.25
- NRIX 36.45
- Support Level
- NDMO $10.36
- NRIX $8.33
- Resistance Level
- NDMO $9.98
- NRIX $10.13
- Average True Range (ATR)
- NDMO 0.12
- NRIX 0.50
- MACD
- NDMO 0.04
- NRIX -0.03
- Stochastic Oscillator
- NDMO 80.56
- NRIX 13.33
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.